Elekta AB (OTCPK:EKTAY)
$ 6.615 0.259 (4.07%) Market Cap: 2.53 Bil Enterprise Value: 3.05 Bil PE Ratio: 23.88 PB Ratio: 2.43 GF Score: 84/100

Q1 2025 Elekta AB (publ) Earnings Call Transcript

Aug 28, 2024 / 08:00AM GMT
Release Date Price: $6.75 (+0.09%)

Key Points

Positve
  • Net sales increased by 1% in constant currencies, driven by strong installations in the US.
  • The book-to-bill ratio improved to 1.10, indicating a solid foundation for future sales growth.
  • Major customer win from the largest private healthcare provider in Mexico, amounting to $64 million.
  • Strong sales growth in the Americas region, with a 16% increase driven by both North and South America.
  • Strategic joint venture with a Chinese software partner to strengthen market position in China.
Negative
  • Gross margins declined year over year to 37.8%, impacted by inflation and reduced inventory revaluation.
  • Adjusted EBIT margin declined to 7.4%, driven by lower gross margins and increased operating expenses.
  • Sales in the Europe, Middle East, and Africa region declined by 12% compared to last year.
  • Continued negative impact from the anti-corruption campaign in China, affecting sales growth.
  • Sequential cash flow after continuous investments amounted to SEK891 million negative, similar to last year.
Peter Nyquist;publ;Head of Investor Relations
Elekta AB

()-

Good morning, everyone. My name is Peter Nyquist, Head of Investor Relations here at Elekta. With me here in Stockholm, I have Gustaf Salford, Elekta's President and CEO; and our CFO, Tobias Hagglov, who will be presenting the results.

Today's agenda starts off with Gustaf, who will present the highlights from the development during the first quarter of the fiscal year '24-'25 as well as the strategic achievements during the quarter. Then Tobias will give you details on the financials and the presentation and then we will end with Gustaf's view on Elekta's outlook. And after the presentation, there will as you usual be time for your questions.

Before we start, I want to remind you that some of the information discussed in this call contains forward-looking statements. This can include projections regarding revenue, operating results, cash flow as well as product and product development. And these statements involve risks and uncertainties that may cause actual results to differ materially from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot